Jessica L. Janes

Jessica L. Janes

Auto-generated profile, based on publicly available information

Jessica L. Janes

Urology Section, Department of Surgery, Veterans Affairs Health Care System, Durham, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2023 in Memory & Cognition
Verified
Journal Article
Closed access
PDF file
Michelle RiversMichelle Rivers
Michelle Rivers
JDJohn Dunlosky
John Dunlosky
JJJessica L. Janes
Jessica L. Janes
AWAmber E Witherby
Amber E Witherby
UTUma Tauber
Uma Tauber

1 January 2020 in Journal of Psychosomatic Research
Verified
Journal Article
Closed access
DCDanette Y. Conklin
Danette Y. Conklin
TGToyomi Goto
Toyomi Goto
SGStephen Ganocy
Stephen Ganocy
SLSana Loue
Sana Loue
CLChristine LaGrotta
Christine LaGrotta
MSMartha M. Sajatovic
Martha M. Sajatovic

23 May 2020 in Applied Cognitive Psychology
Verified
Journal Article
Closed access
PDF file
JJJessica L. Janes
Jessica L. Janes
JDJohn Dunlosky
John Dunlosky
KRKatherine A. Rawson
Katherine A. Rawson
AJAaron Jasnow
Aaron Jasnow

1 September 2022 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
ZKZachary Klaassen
Zachary Klaassen
LHLauren Howard
Lauren Howard
CWChristopher Wallis
Christopher Wallis
JJJessica L. Janes
Jessica L. Janes
AHAmanda De Hoedt
Amanda De Hoedt
SFStephen J. Freedland
Stephen J. Freedland

14 December 2021 in The Prostate
Verified
Journal Article
Closed access
PDF file
SBSean Kennedy Barlow Bs
Sean Kennedy Barlow Bs
TOTaofik Oyekunle
Taofik Oyekunle
JJJessica L. Janes
Jessica L. Janes
AHAmanda M. De Hoedt
Amanda M. De Hoedt
WAWilliam J. Aronson
William J. Aronson
ICIlona Csizmadi
Ilona Csizmadi

13 May 2025 in Cancer Prevention Research
Verified
Journal Article
Closed access
MFMelanie K. Flores
Melanie K. Flores
JJJessica L. Janes
Jessica L. Janes
MIMirajul Islam
Mirajul Islam
JWJunxiang Wan
Junxiang Wan
JLJiali Liu
Jiali Liu
PCPinchas Cohen
Pinchas Cohen
Black individuals are disproportionately burdened by prostate cancer compared with White individuals. The mitochondrion is an untapped source for prostate cancer biomarkers, and previous work has shown that altered mitochondrial DNA (mtDNA) copy number is linked to mitochondrial dysfunction and tumorigenesis. We assess whether mtDNA copy number is altered in patients with and without prostate cancer in a racially specific manner. Circulating cell-free mtDNA copy number from plasma and mtDNA copy number from white blood cells (WBC) were measured in 199 patients undergoing biopsy (50:50 White cases/controls and 50:49 Black cases/controls). mtDNA copy number was determined via Droplet Digital PCR. Logistic regressions tested associations between mtDNA and prostate cancer by race. The AUC was compared between covariate-only models and models with mtDNA. In both plasma and WBCs, mtDNA copy number was significantly increased in cases compared with controls in White patients, but not in Black patients. Interestingly, Black controls had higher mtDNA copy number levels than White controls. Multivariable analysis revealed significant associations of plasma mtDNA and WBC mtDNA with prostate cancer for White patients only. Elevated mtDNA copy number was more accurate in predicting prostate cancer in White patients than in Black patients. Higher mtDNA copy number levels were associated with prostate cancer in both Black and White patients. Plasma mtDNA may be more accurate than WBC mtDNA in predicting prostate cancer incidence in Black men. Overall, Black controls had higher mtDNA copy number levels than White controls, suggesting mtDNA copy number may be implicated in prostate cancer health disparities. Prevention Relevance: Our study shows that mtDNA copy number is a significant predictor of prostate cancer in White individuals, suggesting its potential use in early detection and prevention strategies. The absence of this association in Black individuals highlights the need for race-specific biomarkers in prostate cancer prevention efforts.